Kymera Therapeutics, Inc.
KYMRNASDAQHealthcare● Active
$73.95
$-0.18(-0.24%)
Market Cap$6.1B
P/E Ratio—
52W High$103
52W Low$36.65
Kymera Therapeutics, Inc. (KYMR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
KYMR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
-$0.71
Est. -$0.89 · +20.2%
Revenue
$0.03B
Est. $0.01B · +315.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
KYMR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 10, 2026 | -$0.73 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | -$0.89 | -$0.71 | +20.2% | $0.03B | $0.01B | +315.7% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -$0.78 | -$0.97 | -23.8% | $0.00B | $0.02B | -80.9% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -$0.71 | -$0.90 | -26.8% | $0.00B | $0.01B | -80.9% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.83 | -$0.95 | -14.5% | $0.01B | $0.02B | -33.0% |
| ▲ Q2 FY2025 | May 9, 2025 | -$0.92 | -$0.82 | +10.9% | $0.02B | $0.01B | +78.5% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.76 | -$0.88 | -15.8% | $0.01B | $0.02B | -55.7% |
| ▲ Q4 FY2024 | Oct 31, 2024 | -$0.83 | -$0.82 | +1.2% | $0.00B | $0.02B | -75.4% |
Q3 FY2026
Aug 10, 2026
EPS Actual
—
EPS Est.
-$0.73
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
-$0.71
EPS Est.
-$0.89
EPS Surpr.
+20.2%
Revenue
$0.03B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
-$0.97
EPS Est.
-$0.78
EPS Surpr.
-23.8%
Revenue
$0.00B
Q4 FY2025
Nov 4, 2025Miss
EPS Actual
-$0.90
EPS Est.
-$0.71
EPS Surpr.
-26.8%
Revenue
$0.00B
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.95
EPS Est.
-$0.83
EPS Surpr.
-14.5%
Revenue
$0.01B
Q2 FY2025
May 9, 2025Beat
EPS Actual
-$0.82
EPS Est.
-$0.92
EPS Surpr.
+10.9%
Revenue
$0.02B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$0.88
EPS Est.
-$0.76
EPS Surpr.
-15.8%
Revenue
$0.01B
Q4 FY2024
Oct 31, 2024Beat
EPS Actual
-$0.82
EPS Est.
-$0.83
EPS Surpr.
+1.2%
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-4.42 | $-1.03 | $-0.01 | 6 |
| Q3 FY2027 | $-4.24 | $-0.99 | $-0.01 | 6 |
| Q2 FY2027 | $-4.34 | $-1.01 | $-0.01 | 6 |
| Q1 FY2027 | $-4.29 | $-1.00 | $-0.01 | 6 |
| Q4 FY2026 | $-4.34 | $-1.01 | $-0.01 | 10 |
| Q3 FY2026 | $-1.22 | $-1.02 | $-0.72 | 15 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 13 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +20.2% | $81.51 | $81.07 | -0.54% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -23.8% | $90.68 | $95.03 | +4.80% |
| ▼ Q4 FY2025 | Nov 4, 2025 | -26.8% | $59.72 | $59.91 | +0.32% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -14.5% | $40.62 | $37.68 | -7.24% |
| ▲ Q2 FY2025 | May 9, 2025 | +10.9% | $30.77 | $30.07 | -2.27% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -15.8% | $35.36 | $30.25 | -14.45% |
| ▲ Q4 FY2024 | Oct 31, 2024 | +1.2% | $47.67 | $46.17 | -3.15% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +15.9% | $41.42 | $40.31 | -2.68% |
Q2 FY2026-0.54%
Report Date
Apr 30, 2026
EPS Beat/Miss
+20.2%
Price Before
$81.51
Price After
$81.07
Q1 FY2026+4.80%
Report Date
Feb 26, 2026
EPS Beat/Miss
-23.8%
Price Before
$90.68
Price After
$95.03
Q4 FY2025+0.32%
Report Date
Nov 4, 2025
EPS Beat/Miss
-26.8%
Price Before
$59.72
Price After
$59.91
Q3 FY2025-7.24%
Report Date
Aug 11, 2025
EPS Beat/Miss
-14.5%
Price Before
$40.62
Price After
$37.68
Q2 FY2025-2.27%
Report Date
May 9, 2025
EPS Beat/Miss
+10.9%
Price Before
$30.77
Price After
$30.07
Q1 FY2025-14.45%
Report Date
Feb 27, 2025
EPS Beat/Miss
-15.8%
Price Before
$35.36
Price After
$30.25
Q4 FY2024-3.15%
Report Date
Oct 31, 2024
EPS Beat/Miss
+1.2%
Price Before
$47.67
Price After
$46.17
Q3 FY2024-2.68%
Report Date
Aug 7, 2024
EPS Beat/Miss
+15.9%
Price Before
$41.42
Price After
$40.31
Avg Beat Reaction-2.16%
Avg Miss Reaction-4.14%
Beat Rate4 / 8 quarters
Largest Move-14.45% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: KYMR ends December
Kymera Therapeutics, Inc. (KYMR) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $-0.71 — beating the analyst consensus of $-0.89 by +20.2%. The next KYMR earnings date is expected around September 1, 2026.
Each quarter, investors track KYMR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. KYMR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
KYMR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
KYMR earnings · 5 questionsKymera Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. KYMR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; KYMR historically reports after market close (AMC).
KYMR earnings datewhen is KYMR earningsKYMR next earnings datewhen does KYMR report earningsKYMR earnings calendar
▸ Source: FMP · Kymera Therapeutics, Inc. SEC filings · US GAAP · Kymera Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026